FGD4 (FYVE, RhoGEF and PH domain containing 4)

2006-10-01  

Identity

HGNC
LOCATION
12p11.21
LOCUSID
ALIAS
CMT4H,FRABP,ZFYVE6
FUSION GENES

Other Information

Locus ID:

NCBI: 121512
MIM: 611104
HGNC: 19125
Ensembl: ENSG00000139132

Variants:

dbSNP: 121512
ClinVar: 121512
TCGA: ENSG00000139132
COSMIC: FGD4

RNA/Proteins

Gene IDTranscript IDUniprot
ENSG00000139132ENST00000395740E9PNX0
ENSG00000139132ENST00000427716Q96M96
ENSG00000139132ENST00000472289E9PQT1
ENSG00000139132ENST00000493087E9PNX0
ENSG00000139132ENST00000494977H0YDQ0
ENSG00000139132ENST00000525053E9PJX4
ENSG00000139132ENST00000531134B7Z493
ENSG00000139132ENST00000534526F8VWL3
ENSG00000139132ENST00000546442F8W1R0
ENSG00000139132ENST00000551984F8VVF1
ENSG00000139132ENST00000583694J3KSS3

Expression (GTEx)

0
5
10
15
20
25

Pathways

PathwaySourceExternal ID
Signal TransductionREACTOMER-HSA-162582
Signalling by NGFREACTOMER-HSA-166520
p75 NTR receptor-mediated signallingREACTOMER-HSA-193704
Cell death signalling via NRAGE, NRIF and NADEREACTOMER-HSA-204998
NRAGE signals death through JNKREACTOMER-HSA-193648
Signaling by Rho GTPasesREACTOMER-HSA-194315
Rho GTPase cycleREACTOMER-HSA-194840
Signaling by GPCRREACTOMER-HSA-372790
GPCR downstream signalingREACTOMER-HSA-388396
G alpha (12/13) signalling eventsREACTOMER-HSA-416482

Protein levels (Protein atlas)

Not detected
Low
Medium
High

PharmGKB

Entity IDNameTypeEvidenceAssociationPKPDPMIDs
PA450761paclitaxelChemicalClinicalAnnotationassociatedPD22843789

References

Pubmed IDYearTitleCitations
337097892021Polymorphism of FGD4 and myelosuppression in patients with esophageal squamous cell carcinoma.2
337097892021Polymorphism of FGD4 and myelosuppression in patients with esophageal squamous cell carcinoma.2
318529842020Identification of novel pathogenic copy number variations in Charcot-Marie-Tooth disease.4
326333232020Circular RNA circFGD4 suppresses gastric cancer progression via modulating miR-532-3p/APC/β-catenin signalling pathway.11
327729282020MiR-23a induced the activation of CDC42/PAK1 pathway and cell cycle arrest in human cov434 cells by targeting FGD4.3
318529842020Identification of novel pathogenic copy number variations in Charcot-Marie-Tooth disease.4
326333232020Circular RNA circFGD4 suppresses gastric cancer progression via modulating miR-532-3p/APC/β-catenin signalling pathway.11
327729282020MiR-23a induced the activation of CDC42/PAK1 pathway and cell cycle arrest in human cov434 cells by targeting FGD4.3
305586642018Expression of FGD4 positively correlates with the aggressive phenotype of prostate cancer.7
305586642018Expression of FGD4 positively correlates with the aggressive phenotype of prostate cancer.7
277368462016Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients.18
277368462016Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients.18
264004212015Charcot-Marie-Tooth Disease Type 4H Resulting from Compound Heterozygous Mutations in FGD4 from Nonconsanguineous Korean Families.3
264004212015Charcot-Marie-Tooth Disease Type 4H Resulting from Compound Heterozygous Mutations in FGD4 from Nonconsanguineous Korean Families.3
235508892013A novel mutation in FGD4/FRABIN causes Charcot Marie Tooth disease type 4H in patients from a consanguineous Tunisian family.7

Citation

Dessen P

FGD4 (FYVE, RhoGEF and PH domain containing 4)

Atlas Genet Cytogenet Oncol Haematol. 2006-10-01

Online version: http://atlasgeneticsoncology.org/gene/43262/fgd4-(fyve-rhogef-and-ph-domain-containing-4)